Ignite Creation Date:
2025-12-24 @ 4:48 PM
Ignite Modification Date:
2025-12-27 @ 5:44 PM
Study NCT ID:
NCT00442650
Status:
COMPLETED
Last Update Posted:
2016-11-21
First Post:
2007-02-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2004-01
Start Date Type:
None
Primary Completion Date:
2005-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2005-12
Completion Date Type:
ACTUAL
First Submit Date:
2007-02-28
First Submit QC Date:
None
Study First Post Date:
2007-03-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2016-11-18
Last Update Post Date:
2016-11-21
Last Update Post Date Type:
ESTIMATED